Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology 分享了 ARTISTRY-3 试验的数据，该试验旨在在 ASCO 年会之前评估降低静脉注射频率的 Nemvaleukin Alfa 的影响
Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested, the company said.
该公司表示，Nemvaleukin在 ARTISTRY-3 中证明了其机制的药效学证据，并且在所有测试剂量中总体耐受性良好。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。